- The National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $300K grant to GeoVax Labs (NASDAQ:GOVX +7.5%) to support the development of a Lassa virus vaccine, currently named GEO-LM01. The company says it projects a total project cost of $1.9M following the grant.
- The Lassa virus, named after a town in Nigeria, causes hemorrhagic fever lasting as long three-to-four weeks. 80% of cases are asymptomatic. The mortality rate is ~1%.
GeoVax awarded NIH grant to support development of Lassa virus vaccine; shares up 8%
Recommended For You
More Trending News
About GOVX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
GOVX | - | - |
GeoVax Labs, Inc. |